Your browser version may not work well with NCBI's Web applications. More information here...
1: Curr Opin Investig Drugs. 2004 Nov;5(11):1192-7.Links

COLAL-PRED Alizyme.

Hanauer SB, Sparrow M.

University of Chicago Medical Center, Department of Medicine, Gastroenterology & Nutrition, MC 9028, 5841 S Maryland Avenue, Chicago, IL 60637, USA. shanauer@medicine.bsd.uchicago.edu

COLAL-PRED (prednisolone sodium metasulfobenzoate), which is targeted to the colon by COLAL colonic drug delivery technology, is being developed by Alizyme for the potential treatment of inflammatory bowel disease. Alizyme expect to initiate a phase III trial in 2005.

PMID: 15573870 [PubMed - indexed for MEDLINE]

Recent Activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on